These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 37402471)

  • 1. A phase II study of a doublet metronomic chemotherapy regimen consisting of oral vinorelbine and capecitabine in Chinese women with HER2-negative metastatic breast cancer.
    Chai Y; Liu J; Jiang M; He M; Wang Z; Ma F; Wang J; Yuan P; Luo Y; Xu B; Li Q
    Thorac Cancer; 2023 Aug; 14(23):2259-2268. PubMed ID: 37402471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy study of oral metronomic vinorelbine combined with trastuzumab (mNH) in HER2-positive metastatic breast cancer: a phase II trial.
    Wang Z; Liu J; Ma F; Wang J; Luo Y; Fan Y; Yuan P; Zhang P; Li Q; Li Q; Xu B
    Breast Cancer Res Treat; 2021 Jul; 188(2):441-447. PubMed ID: 33895900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II trial of biweekly vinorelbine and oxaliplatin in second- or third-line metastatic triple-negative breast cancer.
    Zhang J; Wang L; Wang Z; Hu X; Wang B; Cao J; Lv F; Zhen C; Zhang S; Shao Z
    Cancer Biol Ther; 2015; 16(2):225-32. PubMed ID: 25648299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy study of oral metronomic capecitabine combined with pyrotinib in HER2-positive metastatic breast cancer: A phase II trial.
    He M; Liu J; Wang Z; Ma F; Wang J; Zhang P; Li Q; Yuan P; Luo Y; Fan Y; Mo H; Lan B; Li Q; Xu B
    Breast; 2023 Dec; 72():103581. PubMed ID: 37742492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metronomic chemotherapy with oral vinorelbine (mVNR) and capecitabine (mCAPE) in advanced HER2-negative breast cancer patients: is it a way to optimize disease control? Final results of the VICTOR-2 study.
    Cazzaniga ME; Cortesi L; Ferzi A; Scaltriti L; Cicchiello F; Ciccarese M; Della Torre S; Villa F; Giordano M; Verusio C; Nicolini M; Gambaro AR; Zanlorenzi L; Biraghi E; Legramandi L; Rulli E;
    Breast Cancer Res Treat; 2016 Dec; 160(3):501-509. PubMed ID: 27752847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral vinorelbine in combination with trastuzumab as a first-line therapy of metastatic or locally advanced HER2-positive breast cancer.
    Farhat F; Kattan JG; Ghosn M
    Cancer Chemother Pharmacol; 2016 May; 77(5):1069-77. PubMed ID: 27059339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. All-oral combination of oral vinorelbine and capecitabine as first-line chemotherapy in HER2-negative metastatic breast cancer: an International Phase II Trial.
    Tubiana-Mathieu N; Bougnoux P; Becquart D; Chan A; Conte PF; Majois F; Espie M; Morand M; Vaissiere N; Villanova G
    Br J Cancer; 2009 Jul; 101(2):232-7. PubMed ID: 19584872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2-negative endocrine-refractory metastatic breast cancer.
    Shah AN; Flaum L; Helenowski I; Santa-Maria CA; Jain S; Rademaker A; Nelson V; Tsarwhas D; Cristofanilli M; Gradishar W
    J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32060053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metronomic treatment of vinorelbine with oral capecitabine is tolerable in the randomized Phase 2 study XeNa including patients with HER2 non-amplified metastatic breast cancer.
    Brems-Eskildsen AS; Linnet S; Danø H; Luczak A; Vestlev PM; Jakobsen EH; Neimann J; Jensen CB; Dongsgaard T; Langkjer ST
    Acta Oncol; 2021 Feb; 60(2):157-164. PubMed ID: 33259244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Final Results of the Randomized Phase II NorCap-CA223 Trial Comparing First-Line All-Oral Versus Taxane-Based Chemotherapy for HER2-Negative Metastatic Breast Cancer.
    Cinieri S; Chan A; Altundag K; Vandebroek A; Tubiana-Mathieu N; Barnadas A; Dodyk P; Lazzarelli S; Botha M; Rauch D; Villanova G; Coskun U
    Clin Breast Cancer; 2017 Apr; 17(2):91-99.e1. PubMed ID: 27756583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of Metronomic Oral Vinorelbine, Cyclophosphamide, and Capecitabine vs Weekly Intravenous Paclitaxel in Patients With Estrogen Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: Final Results From the Phase 2 METEORA-II Randomized Clinical Trial.
    Munzone E; Regan MM; Cinieri S; Montagna E; Orlando L; Shi R; Campadelli E; Gianni L; Palleschi M; Petrelli F; Bengala C; Generali D; Collovà E; Puglisi F; Cretella E; Zamagni C; Chini C; Ruepp B; Loi S; Colleoni M;
    JAMA Oncol; 2023 Sep; 9(9):1267-1272. PubMed ID: 37440239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of a triple combination of oral vinorelbine, capecitabine and trastuzumab as first-line treatment in HER2-positive metastatic breast cancer.
    Chan A; Conte PF; Petruzelka L; Tubiana-Mathieu N; Ganju V; Llombart A; Espie M; Majois F; Gil MG; Vaissiere N; Villanova G
    Anticancer Res; 2013 Jun; 33(6):2657-64. PubMed ID: 23749924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficiency and safety of low-dose apatinib combined with oral vinorelbine in pretreated HER2-negative metastatic breast cancer.
    Huang JY; Chen XL; Xie XF; Song L; Chen LP; Lan XF; Bai X; Chen X; Du CW
    Cancer Med; 2024 Apr; 13(8):e7181. PubMed ID: 38659376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metronomic oral combination chemotherapy with capecitabine and cyclophosphamide: a phase II study in patients with HER2-negative metastatic breast cancer.
    Yoshimoto M; Takao S; Hirata M; Okamoto Y; Yamashita S; Kawaguchi Y; Takami M; Furusawa H; Morita S; Abe C; Sakamoto J
    Cancer Chemother Pharmacol; 2012 Aug; 70(2):331-8. PubMed ID: 22526409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-agent metronomic versus weekly oral vinorelbine as first-line chemotherapy in patients with HR-positive/HER2-negative advanced breast cancer: The randomized Tempo Breast study.
    Freyer G; Martinez-Jañez N; Kukielka-Budny B; Ulanska M; Bourgeois H; Muñoz M; Morales S; Calero JB; Cortesi L; Pintér T; Palácová M; Cherciu N; Petru E; Ettl J; de Almeida C; Villanova G; Raymond R; Minh CTT; Rodrigues A; Cazzaniga ME
    Breast; 2024 Apr; 74():103681. PubMed ID: 38377732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. All-oral combination of vinorelbine and capecitabine as first-line treatment in HER2/Neu-negative metastatic breast cancer.
    Tawfik H; Rostom Y; Elghazaly H
    Cancer Chemother Pharmacol; 2013 Apr; 71(4):913-9. PubMed ID: 23344713
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Capecitabine and bevacizumab with or without vinorelbine in first-line treatment of HER2/neu-negative metastatic or locally advanced breast cancer: final efficacy and safety data of the randomised, open-label superiority phase 3 CARIN trial.
    Welt A; Marschner N; Lerchenmueller C; Decker T; Steffens CC; Koehler A; Depenbusch R; Busies S; Hegewisch-Becker S
    Breast Cancer Res Treat; 2016 Feb; 156(1):97-107. PubMed ID: 26927446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Efficacy and toxicity of vinorelbine (NVB)-based regimens in patients with metastatic triple negative breast cancer (mTNBC) pretreated with anthracyclines and taxanes].
    Du F; Yuan P; Luo Y; Wang J; Ma F; Cai R; Fan Y; Li Q; Zhang P; Xu B
    Zhonghua Zhong Liu Za Zhi; 2015 Oct; 37(10):788-92. PubMed ID: 26813602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I trial of oral metronomic vinorelbine plus capecitabine in patients with metastatic breast cancer.
    Saridaki Z; Malamos N; Kourakos P; Polyzos A; Ardavanis A; Androulakis N; Kalbakis K; Vamvakas L; Georgoulias V; Mavroudis D
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):35-42. PubMed ID: 21590447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of vinorelbine in combination with pertuzumab and trastuzumab for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer: VELVET Cohort 1 final results.
    Perez EA; López-Vega JM; Petit T; Zamagni C; Easton V; Kamber J; Restuccia E; Andersson M
    Breast Cancer Res; 2016 Dec; 18(1):126. PubMed ID: 27955684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.